Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACILE: Ribociclib + NSAI in Elderly Breast Cancer
NCT03944434Phase 2Active, not recruiting
- Sponsor
- Fondazione Sandro Pitigliani
- Start
- Dec 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Fondazione Sandro Pitigliani. Primary endpoint: Treatment feasibility at 6 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03944434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944434.